Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Lilly Invests $700M in Insulin Manufacturing Capacity

Published: Friday, November 15, 2013
Last Updated: Friday, November 15, 2013
Bookmark and Share
The investments are a direct response to the growing diabetes epidemic.

Eli Lilly and Company announced it will invest more than $700 million to enhance its global insulin manufacturing capacity in Puerto Rico, France and China, as well as in Indianapolis, home to Lilly's global headquarters. Today's news raises Lilly's manufacturing commitment in the past year to more than $1 billion in planned investments in response to the growing diabetes epidemic and increasing demand for insulin around the world.

Nearly half of the $1 billion investment will improve Indianapolis sites, where Lilly has been manufacturing insulin since it introduced the first commercially available insulin product in 1923.

According to the International Diabetes Federation (IDF)—which today released the latest diabetes prevalence numbers—diabetes is a significant and growing global problem, with high and increasing costs to society and to individuals. The IDF also noted that all types of diabetes are on the rise, with the number of people with type 2 diabetes increasing most dramatically.[i]

"Insulin is a cornerstone of diabetes treatment and its use will only continue to increase given the rising number of people with diabetes around the world," said Enrique Conterno, senior vice president and president, Lilly Diabetes. "Since introducing the first commercially available insulin 90 years ago, Lilly has helped address the global diabetes burden, and today's announcement further underscores our deep commitment to diabetes care."

In addition to committing to investments in manufacturing, the company is investing heavily in diabetes research. Lilly currently has 14 new molecular entities in clinical development, including three under regulatory review and another in Phase III, for the treatment of diabetes and related complications.

The new manufacturing investments will support both existing and future insulin-based medicines and are as follows:

• France — $120 million to enhance insulin cartridge manufacturing capacity

• Indianapolis and Puerto Rico — $245 million to expand insulin-active-ingredient and delivery device manufacturing capacity

• China — $350 million to expand insulin cartridge manufacturing capacity

The commitment to expand insulin production in China is the latest in a series of diabetes-related investments in this part of the world, such as the opening of the Lilly China Research and Development Center in Shanghai last year. According to the IDF, there are almost 100 million people in China with diabetes, with as many as three-quarters of them not having adequate control of their disease.

"The burden of diabetes knows no boundaries," said Jacques Tapiero, senior vice president and president, Lilly Emerging Markets. "In particular, our ongoing investment in China will help Lilly bring medicines to the country with the largest population of people with diabetes—and which is projected to rise to more than 142 million by 2035."

Prior to today's announcement, Lilly recently communicated insulin-related commitments in Indianapolis totaling $320 million to expand insulin-active-ingredient and drug product manufacturing capacity, as well as an additional $80 million in ancillary projects. Together, these announcements bring the total commitment over the past year to more than $1 billion, which will be invested over the next several years.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Approval for Lilly's Gastric Cancer Drug
CYRAMZA now approved both as a single-agent treatment and in combination with chemotherapy.
Monday, November 10, 2014
Lilly, Zymeworks Expand Strategic Licensing and Collaboration Agreement
Zymeworks Inc. and Eli Lilly and Company are expanding their existing licensing and collaboration agreement.
Friday, October 24, 2014
Lilly to Close One of Three Manufacturing Operations in Puerto Rico
Manufacturing at Guayama will conclude while investments continue in Carolina.
Friday, October 17, 2014
Lilly to Acquire Novartis Animal Health
$5.4 billion deal creates world's second-largest animal health company.
Thursday, September 18, 2014
Lilly Provides Update on Next Steps for Solanezumab
Eli Lilly and Company provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease.
Thursday, December 13, 2012
Applied NeuroSolutions Announces Renewal of Alzheimer’s Disease Drug Discovery Collaboration with Eli Lilly
Lilly will pay $250,000 to Applied NeuroSolutions for the one-year collaboration renewal.
Wednesday, December 09, 2009
Lilly Completes Acquisition of ImClone Systems
The acquisition will broaden Lilly's portfolio of marketed cancer therapies and oncology pipeline with up to three targeted therapies in Phase III in 2009.
Tuesday, November 25, 2008
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
The collaboration will apply Deciphera's phylomechanics platform with Lilly's expertise to study B-Raf kinase inhibitors for cancer treatments.
Monday, October 06, 2008
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Late-stage IDENTITY study of once-daily, oral agent is now enrolling patients.
Wednesday, April 02, 2008
Lilly and BioMS Medical Announce Global Licensing and Development Agreement
Lilly to acquire exclusive rights to late-stage molecule for the treatment of multiple sclerosis.
Wednesday, December 19, 2007
Lilly Breast Cancer Studies Explore Potential Role of Pharmacogenomics in Customizing Chemotherapy
Lilly has unveiled two breast cancer studies involving pharmacogenomics and its chemotherapies GEMZAR® (gemcitabine HCl) and ALIMTA® (pemetrexed).
Tuesday, June 06, 2006
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Michigan Researchers Use Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos